Sugi Predict

Sugi Predict / Compounds / SCHEMBL24041

SCHEMBL24041

SCHEMBL24041

O=C(Cl)/C=C/CN1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ELANE P08246 5/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CHRNB2 P17787 1/20 0.34
▸ CHRNB4 P30926 1/20 0.34
▸ CHRNA3 P32297 1/20 0.34
▸ CHRNA4 P43681 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24042 1.00 MAPT (0.38) MAPTALDH1A1GAAPOLBL3MBTL1
Hydrochloric Acid SCHEMBL18979114 0.98 ELANE (0.36) MAPTALDH1A1GAAPOLBL3MBTL1
SCHEMBL508801 0.98 MAPT (0.34) MAPTALDH1A1GAAPOLBL3MBTL1
SCHEMBL508802 0.98 MAPT (0.34) MAPTALDH1A1GAAPOLBL3MBTL1
SCHEMBL3485834 0.94 ELANE (0.31) MAPTALDH1A1GAAPOLBELANE
SCHEMBL2228719 0.94 ELANE (0.31) MAPTALDH1A1GAAPOLBELANE
SCHEMBL2972245 0.81 CYP1A2 (0.41) MAPTALDH1A1GAAPOLBL3MBTL1
SCHEMBL22660298 0.81 ALDH1A1 (0.39) MAPTALDH1A1GAAPOLBL3MBTL1
SCHEMBL24306 0.81 CYP1A2 (0.41) MAPTALDH1A1GAAPOLBL3MBTL1
SCHEMBL2972244 0.81 CYP1A2 (0.41) MAPTALDH1A1GAAPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116217437-A Dacotinib intermediate, dacotinib and preparation method of Dacotinib 沈阳药科大学 2023-06-06 — — CN claimed
CN-116217437-B Dacotinib intermediate, dacotinib and preparation method of Dacotinib 沈阳药科大学 2025-02-11 — — CN disclosed
CN-116217437-B Dacotinib intermediate, dacotinib and preparation method of Dacotinib 沈阳药科大学 2025-02-11 — — CN disclosed
US-20240246934-A1 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2024-07-25 — — US disclosed
CN-115109036-B Quinazoline compound, composition and application thereof 北京赛特明强医药科技有限公司 2024-06-11 — — CN disclosed
EP-4293016-A1 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2023-12-20 — — EP disclosed
CN-116217437-A Dacotinib intermediate, dacotinib and preparation method of Dacotinib 沈阳药科大学 2023-06-06 — — CN disclosed
CN-116217437-A Dacotinib intermediate, dacotinib and preparation method of Dacotinib 沈阳药科大学 2023-06-06 — — CN disclosed
CN-115109036-A Quinazoline compound, composition and application thereof 北京赛特明强医药科技有限公司 2022-09-27 — — CN disclosed
WO-2022194265-A1 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND 北京赛特明强医药科技有限公司 2022-09-22 — — WO disclosed
US-20110262877-A1 HEAT TREATMENT APPARATUS IHI CORPORATION (JP) 2011-10-27 — — US disclosed
US-7772243-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2010-08-10 — — US disclosed
US-7772243-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2010-08-10 — — US disclosed
US-7772243-B2 4-phenylamino-quinazolin-6-yl-amides WARNER-LAMBERT COMPANY LLC (US) 2010-08-10 — — US disclosed
US-20100190977-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES PFIZER INC. 2010-07-29 — — US disclosed
US-20100190977-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES PFIZER INC. 2010-07-29 — — US disclosed
US-20100190977-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES PFIZER INC. 2010-07-29 — — US disclosed
EP-1746999-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES Warner-Lambert Company LLC (US) 2007-01-31 — — EP disclosed
WO-2005107758-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES WARNER-LAMBERT COMPANY LLC (US) 2005-11-17 — — WO disclosed
US-20050250761-A1 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis PFIZER INC 2005-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246934-A1 QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND ABL1, ERBB2, EGFR MAPT 3240/4885ALDH1A1 4496/4885GAA 2467/4885
US-20100190977-A1 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES HRH4, HRH3, HRH2 MAPT 4679/4885ALDH1A1 2418/4885GAA 3770/4885
US-20050250761-A1 such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis JAK1, JAK2, EDNRA MAPT 4367/4885ALDH1A1 2971/4885GAA 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.